Friday, 26 April 2024
Protagonist Therapeutics Inc
NASDAQ : PTGX
7.990 14 Oct 22 00:00 | Change: 0.35 | Open: 8.390 | High: 8.510 | Ask: 0.000 | Volume: 593,400 |
Change(%): 4.20 | Prev: 8.340 | Low: 7.940 | Bid: 0.000 | Avg vol: 0 |
Analysts expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to report $-0.99 EPS on March, 6.They anticipate $0.32 EPS change or 47.76 % from last quarter's $-0.67 EPS.
more»
22:33 | 2/2/18
StockNewsTimes
Protagonist Therapeutics logo Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 875 shares of the firm's stock in a transaction on Tuesday, January 16th.
more»
01:56 | 1/2/18
PR Newswire
The alpha-4-beta-7 integrin antagonist PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist PTG-200 is currently being studied in a Phase 1 clinical trial in ...
more»
Protagonist is also expected to release phase 1 results for PTG-200 in Crohn's disease in the second quarter, and the firm's partnership with Johnson & Johnson (NYSE: JNJ)'s Janssen could yield a potential $990 million in milestones plus royalties ...
more»
17:18 | 14/1/18
Concord Register
Protagonist Therapeutics, Inc. (:PTGX) closed at $19.84 after seeing 53847 shares trade hands during the most recent session.
more»
There are currently no comments on this topic.
Be the first person to Add a Comment...
You must be a registered user to post a comment: REGISTER NOW
If you are already registered, please LOGIN NOW
|
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |